First Time Disclosures from Rome
The First Time Disclosures session at ACS Fall 2024 in Denver, organized by the MEDI Division of ACS, presented 13 innovative small molecules in clinical development, including Novartis’ IWY357 and Vividion’s KEAP1 covalent activator.
Highlighted Terms
Related News
First Time Disclosures from Rome
The First Time Disclosures session at ACS Fall 2024 in Denver, organized by the MEDI Division of ACS, presented 13 innovative small molecules in clinical development, including Novartis’ IWY357 and Vividion’s KEAP1 covalent activator.